2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
05/15/19ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference
LOS ANGELES, May 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with institutional investors throughout ... 
Printer Friendly Version
05/09/19ChromaDex Corporation Reports First Quarter 2019 Financial Results
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased marketing efficiency Continued progress building TRU NIAGEN into a global brand with top-line momentum TRU NIAGEN net sales were $7.5 million, a 15% increase sequentially and a 146% increase year-over-year Global expansion continued with e-Commerce roll-out in Canada... 
Printer Friendly Version
05/09/19ChromaDex Announces $10 Million Issuance of Convertible Notes
Private Placement Led by High Profile Venture Capitalists and Strategic Investors LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The conver... 
Printer Friendly Version
05/02/19ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
LOS ANGELES, May 02, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discus... 
Printer Friendly Version
04/24/19ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies
Distribution agreement for Tru Niagen (nicotinamide riboside) in Vancouver area provides access to high-end pharmacies and clinics LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other allied health businesses. According to Orbis Research, the $250 billio... 
Printer Friendly Version
04/15/19ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada
ChromaDex flagship Tru Niagen (nicotinamide riboside) product now available in Showcase specialty retail stores in Canada LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the greater Toronto area as well as Showcase’s online store. Showcase operates 118... 
Printer Friendly Version
04/09/19New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
Data published in the Journal of American College of Cardiology shows that this novel form of vitamin B3 helps maintain mitochondrial function in an animal model by stimulating a cellular repair pathway; preliminary human data also support future testing of NR in connection with cardiac health LOS ANGELES--(BUSINESS WIRE)--Apr. 9, 2019-- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that sup... 
Printer Friendly Version
04/03/19Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP’s Sixth Annual Biohacking Conference
World’s leading expert on NAD metabolism to speak at #UpgradeXP2019 LOS ANGELES, April 03, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking Conference, a three-day immersive experience for the human performance industry.  Hosted by Upgrade Labs, the conference runs Friday, April... 
Printer Friendly Version
03/11/19ChromaDex to Present at the 31st Annual ROTH Conference
LOS ANGELES, March 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with instit... 
Printer Friendly Version
03/08/19ChromaDex Brings TRU NIAGEN® to SXSW® 2019
TRU NIAGEN® milestones to be highlighted at South by Southwest® SXSW® gathering of global professionals LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide riboside) ingredient. "To help SXSW® attendees who need an extra boost in their busy lives, we'll b... 
Printer Friendly Version
03/07/19ChromaDex Corporation Reports 2018 Financial Results
- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and supply agreement with Nestlé Health Science (“NHSc”), which provides NHSc with the exclusive right to include TRU NIAGEN® in its branded medical nutrition products and co-exclusive rights to include TRU NIAGEN in its protein based ready to drink or loose powder bever... 
Printer Friendly Version
03/01/19ChromaDex to Present at the 39th Annual Cowen Health Care Conference
LOS ANGELES, March 01, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA. The ChromaDex management team is scheduled to present on Monday, March 11, at 4:50 p.m. ET. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. The ... 
Printer Friendly Version
02/28/19ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31, 2018. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to ... 
Printer Friendly Version
01/23/19New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
Landmark preclinical lactation study of unique form of vitamin B3 (nicotinamide riboside) showing remarkable results in rodents published in Cell Reports LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conduct... 
Printer Friendly Version
01/22/19ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Health
ChromaDex to move forward with patent infringement action, following unsuccessful challenge by Elysium Health during Inter Partes Review (IPR) LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.’s challenge to Claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.  ChromaDex reported on January 22, 2018 that the PTAB denied Elysium... 
Printer Friendly Version